Accession Number:



Chemotherapy of Cutaneous Leishmaniasis

Descriptive Note:

Technical Report,01 Sep 2010,31 Dec 2012

Corporate Author:

University of Miami Miami United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Two antileishmanial test systems MLS and MLL were used to evaluate compounds at one or more levels. These test systems used female BALBc mice infected with Leishmania major. There were 11 MLS tests done and 242 compounds used. The following 19 compounds were active BU55197, BU5504,BP20206, BQ90098, BQ90552, BS81946, BS83191, BS86085,BU30118, BQ90981, BQ92145, AQ52825, BS04930, BS80690, BS93553, BU26730, BU59640, BS84858 and BU68416. In the MLS test parasites were injected intradermally ID at the base of the tail. Drug treatment was started on day 3 post infection IP for 10 days. In addition, 13 MLL tests were done and 113 compounds used. Results indicated 4 actives BG32694,BU59640, BU59640 and BU68452. In the MLL test, mice were infected ID at the base of the tail and treatment was started IP for 10 days when the lesions reached between 20-70 mm2. AmBiosome was used as the positive control for all test systems. The Oracle database was used for tabulation of data and statistically analyzing the results.

Subject Categories:

Distribution Statement: